VANCOUVER, BC and MENLO PARK, CA -- (Marketwired) -- 08/12/13 -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company hosted a symposium entitled "VAL-083 for Newly Diagnosed GBM Patients with Unmethylated MGMT Promoter" at the 10th Annual Meeting of the Chinese Society for NeuroOncology (CSNO), in Kunming, China on August 10, 2013.
The DelMar session, which was led by Professor ZongPing Chen, chair of the Chinese Society for NeuroOncology, brought together more than 40 leading Chinese neurosurgeons and oncologists to discuss VAL-083 as a potential front-line therapy for glioblastoma patients whose tumors feature high expression of MGMT, a repair enzyme that makes the cancer unlikely to respond to Temodar®, the current standard-of-care. During the session, Dr. Kent Shih presented an overview of VAL-083, a rationale for front-line therapy, and a proposed front-line trial design for discussion among the symposium attendees and DelMar management.
Dr. Shih is a clinical oncologist and a lead investigator in DelMar's ongoing clinical trial for refractory glioblastoma in the United States. Dr. Shih's presentation at the CSNO meeting highlighted the following: 1) the unique mechanism of VAL-083; 2) the drug's activity against newly diagnosed GBM based on published literature from historical clinical trials, and; 3) the recent promising results of DelMar's ongoing clinical trial in refractory GBM.
DelMar is currently conducting a Phase I/II dose-escalation study designed to assess the safety and efficacy of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma multiforme (GBM) and secondary brain tumors who have failed standard therapies and have no viable treatment options.
Jeffrey Bacha, DelMar's president & CEO said, "We were very pleased to have this opportunity to introduce our rationale for commencing a clinical trial in newly-diagnosed GBM at this year's CSNO meeting. We plan to work closely with our clinical advisors to design and initiate this trial, which could potentially provide a new treatment option for patients who have been newly diagnosed with glioblastoma and have been identified as unlikely to respond to the current standard of care."
VAL-083 is currently approved in China for the treatment of chronic myelogenous leukemia and lung cancer. DelMar has established a collaboration and exclusive supply agreement with Guangxi Wuzhou Pharmaceuticals, the only company licensed by the Chinese Food and Drug Administration to manufacture VAL-083 as a cancer therapy. Under the terms of the collaboration, DelMar and Guangxi Wuzhou Pharmaceuticals are working together to ensure the product specifications meet global standards in order to accelerate international development and regulatory approval for VAL-083 on a worldwide basis. Guangxi Wuzhou Pharmaceuticals will provide funding for clinical trials conducted in China and will be the exclusive supplier of DAG for injection and DelMar will be responsible for development and commercialization. DelMar is currently seeking to establish a separate collaboration for the distribution, sales and marketing of VAL-083 in China.
Most Popular Stories
- American Airlines, US Airways Complete Merger
- ACA Delay Stresses Small Businesses
- Questions Remain in Jenni Rivera's Death
- Unemployed Wait as Lawmakers Debate
- General Dynamics Plans 200 New Jobs in N.M.
- Harley Issues Motorcycle Recall
- Dell Offers Undisclosed Number of Employee Buyouts
- Auto Dealer Builds Big Solar Project
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Entrepreneurs' Next Creation May Be New Laws